THE INVESTOR

▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald

Bio

October 30, 2019
Celltrion’s Remsima logs $77m US sales in Q3

Sales of biosimilar Remsima by South Korean bio-pharmaceutical firm Celltrion reached $77 million in the United States during the third quarter of this year, industry data showed Oct. 30. Sales of the biosimilar drug to treat autoimmune diseases jumped 8 percent on-year during the July-Septembe...
October 27, 2019
Korean pharmas flock to CPhI Worldwide 2019

The 30th CPhI Worldwide 2019, the biggest global event of the year for the pharmaceutical industry, is set to take place at Messe Frankfurt in Germany from Nov. 5 to 7. Every year, CPhI brings together more than 100,000 pharmaceutical professionals to network for business opportunities at venues a...
October 25, 2019
Bridge Biotherapeutics receives preliminary screening approval for Kosdaq listing

South Korean biotech firm Bridge Biotherapeutics announced Oct. 25 that it had received preliminary screening approval for Kosdaq listing. The company applied for approval Sept. 3 and expects to be listed on the second-tier Kosdaq market in December this year. “We will continue to develop and ad...
October 17, 2019
Ministry orders Medytox to scrap Meditoxin inventory for exports

The Ministry of Food and Drug Safety on Oct. 16 ordered Medytox to withdraw and dispose of the entire batch of its botulinum toxin Meditoxin produced for exports. The problematic products were produced on Oct 6, 10 and 19 of 2016 and its expiry date is Oct 5, 11 and 18 this year, respectively. The...
October 17, 2019
Daewoong launches botulinum toxin in Canada

Daewoong Pharmaceutical announced Oct. 16 it has launched its botulinum toxin under the name Nuceiva in Canada. It is the first South Korean company to enter the Canadian market with a botulinum toxin brand. “Like the US market, Canada also has only three types of botulinum toxins which have bee...
October 16, 2019
Top court suspends FSC’s penalties on Samsung BioLogics

South Korea’s Supreme Court announced on Oct. 16 that it has approved a request by Samsung BioLogics to suspend the execution of penalties by the financial watchdog on Oct. 11. The court’s recent decision came after the lower courts approved the same request of Samsung BioLogics in February an...
October 07, 2019
Daewoong Pharma denies Medytox’s recent claims on Nabota

Daewoong Pharmaceutical on Oct. 7 denied allegations by Medytox that it stole manufacturing secrets, including its Hall A Hyper strain, to develop its botulinum toxin Nabota. “Medytox is saying that its Hall A Hyper strain, which was proven to not form spores by multiple professionals for decades...
October 02, 2019
Daewoong gets nod for Nabota in Europe

South Korean drugmaker Daewoong Pharmaceutical said Oct, 2 it has won approval from European authorities for the sale of its botulinum toxin product. The European Commission accepted Daewoong’s application to sell Nabota, Korea’s first botulinum toxin product to receive the green light for th...
October 01, 2019
Samsung BioLogics wins lawsuit against Lonza

Samsung BioLogics has won a lawsuit against Switzerland-based Lonza to nullify its patents involving its cell line development technology in South Korea, according to sources Oct. 1. The court noted Lonza’s patented technology is not new compared to the one that is being widely used and it is als...
September 27, 2019
Genexine establishes JV in Thailand

South Korean biotech firm Genexine announced on Sept. 27 that it has signed a contract with the Thai company KinGen Holdings to establish a 50:50 joint venture named KinGen Biotech. KinGen Holdings is a Thai consortium that is backed by the government, schools and divers investors, according to Ge...
September 27, 2019
Celltrion Healthcare seeks expansion in Middle East

Celltrion Healthcare on Sept. 27 announced its decision to expand sales in the Middle East. He company has got approval to exclusively supply Remsima, its version of Johnson & Johnson’s Remicade from the third quarter this year. According to the company, its successful bid was due to its aggress...
September 23, 2019
Celltrion’s Remsima SC close to sales approval in EU

Celltrion Group on Sept. 20 announced that European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended giving sales approval for Remsima SC. CHMP is responsible for preparing the opinions to EMA on questions concerning human medicines based on scientific evidence. ...
September 16, 2019
Medytox invests in US startup LifeSprout

Medytox has participated in the seed-funding round of US startup LifeSprout, according to industry sources on Sept. 16. Although the Korean company declined to confirm the specific amount that it has funded, a local news outlet reported that it invested around $1.5 million in this round. The US c...
September 15, 2019
S. Korean drug firms eye growth in South America

Korean pharmaceutical companies are making inroads into the Central and South American markets, betting on their steady growth. Samsung Bioepis, Celltrion Healthcare, Boryung Pharmaceutical, CJ HealthCare and Hanmi Pharmaceutical all announced in the first half of 2019 that they would begin or exp...
September 10, 2019
Celltrion’s Herzuma receives sales approval in Canada

South Korean biopharmaceutical firm Celltrion announced Sept. 10 that its breast cancer biosimilar has been approved for sales in Canada. The regulatory body Health Canada has approved the data from nonclinical and clinical trials, and announced that Herzuma’s safety and effectiveness are compara...

1 2 3 4 5 6 7 8 9 10

EDITOR'S PICKS

Herald Corporation |CEO : Choi Jin-Young |Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea |Title : The Investor |Date of registration : 2016.06.21 |Date of issue : 2016.06.21
Publisher. Editor : Choi Jin-Young |Chief Privacy Officer & Juvenile Protection Manager : Choi He-suk |T +82-2-727-0021 |E investor@heraldcorp.com

FAMILY SITE GO

Company Registration No. 104-81-06004 |Mail-Order Business Registration 2016 - Seoul Yongsan - 00590 |Business info |Gov’t registration No. Seoul 아04099